FDA
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
-
-
-
-
-
-
-
Adeptus Biotechnologies Corp. (ADPT) PT Raised to $9 at BTIG
-
-
-
-
-
-
-
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Announces Launch of Epic Integration for clonoSEQ
-
-
-
-
-
-
-
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
-
-
-
-
-
-
-
Adaptive Biotechnologies (ADPT) Partners with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
-
-
-
-
-
-
-
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

